{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-010765","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.842366+00:00","generated_at":"2026-06-11T11:34:34.053108+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ENDRA files FDA De Novo for TAEUS liver system; Q2 loss $2.6M, cash $4.8M","bullets":["Submitted De Novo request to FDA for TAEUS liver fat assessment system; clinical data showed 90% sensitivity and correlation r=0.78 vs MRI-PDFF.","Q2 2023 net loss $2.6M ($0.43/share) vs $3.6M ($1.17) in Q2 2022; operating expenses fell to $3.0M from $3.6M.","Cash and equivalents $4.8M at June 30; $4.7M net raised in May 2023 public offering to extend runway through key 2023 milestones.","IP portfolio expanded to 64 issued patents globally; four new patents issued in Q2 (one US, three China)."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-010765","json":"https://secwatch.observer/filing/0001654954-23-010765.json","markdown":"https://secwatch.observer/filing/0001654954-23-010765.md","text":"https://secwatch.observer/filing/0001654954-23-010765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423010765/0001654954-23-010765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423010765/ndra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:34:34.053108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51b2b4914cf7f3fc0b5f4ab979d72ab9b436bdde","claim":"ENDRA Life Sciences Inc. reported the quarter ended June 30, 2023 results: net income Net loss in the second quarter of 2023 was $2.6 million, or $0.43 per share, EPS $0.43 per share.","evidence_excerpt":"On August 14, 2023, ENDRA Life Sciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423010765/0001654954-23-010765-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss in the second quarter of 2023 was $2.6 million, or $0.43 per share"},{"label":"EPS","value":"$0.43 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}